UNSPSC 51334414: Propyperone

This classification denotes an anxiolytic with the molecular formula C23H33FN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HG22108KQK, chemically known as 1-butanone, 1-(4-fluorophenyl)-4-(4-(1-oxopropyl)(1,4-bipiperidin)-1-yl)- (9ci) but generally known as propyperone, which bears US NIH Compound Identifier 19607. European Medicines Agency schedules Propyperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10124MIG.

UNSPSC 51334414 Propyperone is a Commodity code that does not align with actual state and local procurement activity documented in recent solicitations. The code's nominal scope covers a specific chemical precursor, yet the three representative opportunities posted in 2026 involve naloxone procurement, therapeutic pharmacy initiatives, and generic multi-source pharmaceuticals—none of which relate to propyperone. The mismatch suggests either a classification error in how opportunities are tagged or a code with minimal real procurement activity in the state and local market. State and local issuers tagging opportunities under this code appear to be health and human services agencies, including county health departments, state HHS commissions, and cooperative purchasing alliances, but the actual commodities being solicited (naloxone, OTC products, direct-to-manufacturer prescription programs) do not fit the propyperone category.

The issuing bodies across recent opportunities span Seminole County, Florida; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP). Geographic activity centers on Florida, Texas, and Minnesota, with MMCAP's cooperative vehicle extending reach to Oregon and other participating states. Recent solicitations include Seminole County's IFB60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription programs; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic pharmaceuticals and OTC products. Given the disconnect between code and opportunity scope, firms should verify code assignments before pursuit; the propyperone code shows little relevant recent state and local activity.